The drug, which hits a key growth-promoting molecule inside cells, called mTOR, is also showing surprising preliminary promise in treating advanced breast cancer patients.

FORBES: Magazine Article

Celldex enrolled 120 patients with advanced breast cancer that over-expresses a protein known as GPNMB (confirmed by an independent test).

FORBES: 7 Cancer Drug Stocks to Know Right Now